Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Cancer Res. 2009 Apr 14;69(10):4150–4158. doi: 10.1158/0008-5472.CAN-08-3203

Figure 5.

Figure 5

In vivo effect of AZD 1152 treatment on Umbilical Cord Blood Cells. One round of AZD1152 treatment at 25mg/kg/day severely reduced the level of human CB-derived xenografts. Although when left post treatment for 5 more weeks before analysis the level of CB-derived graft was slightly higher. Further treatment with another round of 1-week AZD1152 treatment did not completely eradicate the human grafts. Statistical significance (p<0.05) is indicated by *.